National Cultures and International Competition: The Experience of Schering AG, 18511950: The Experience of Schering AG, 1851-1950 (Cambridge Studies in the Emergence of Global Enterprise)
The IN VIVO Blog (Free subscription) | 06/11/2009
In case you failed to run a Google search this week, you may not have realized that on Tuesday Nov. 10, Sesame Street turns 40 . You gotta admit, the show doesn't look a day over five--and that's without Botox. If you've forgotten how to get to Sesame Street , we have a few reminders--and ear worms -- appropriately tailored for the biopharma industry--hey, it's our version of personalized medicine...
PharmaGossip (Free subscription) | 05/11/2009
To Schering we bid our fondest adieu; Founder Ernst might weep at the shame. Your German sibling has shuffled off, too, But Bayer, at least, saved his name. Source
Seattle Times (Free subscription) | 04/11/2009
A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough.
Seattle Post-Intelligencer (Free subscription) | 04/11/2009
NEW YORK -- A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough.
Stocks to Watch Today (Free subscription) | 04/11/2009
Merck, as expected, closes on Schering acquisition
Philadelphia Inquirer (Free subscription) | 04/11/2009
Merck & Co. Inc. completed its planned $41 billion acquisition of Schering-Plough Corp. yesterday after the stock markets closed. The deal creates the world's second-largest drugmaker, behind Pfizer Inc. Patent expirations on top-selling drugs such as Merck's asthma drug Singulair helped drive the combination.
Star Tribune (Free subscription) | 02/11/2009
After 28 weeks of treatment, Schering-Plough said 25 percent of the null responders had a "sustained virologic response," meaning their virus levels were too low to measure. After 48 weeks of treatment, 55 percent of patients had a sustained virologic response.
ABC News (Free subscription) | 02/11/2009
Schering posts boceprevir trial data, including results for patients not helped by other drugs
43(B)log (Free subscription) | 31/10/2009
Schering-Plough Healthcare Products, Inc. v. Schwarz Pharma, Inc., -- F.3d --, 2009 WL 3460808 (7th Cir.) As entertaining as a Posner opinion always is, I fear this one has more than enough casual language in it to do mischief to the law; it will likely be much cited, whether for heat or for light. Discussion of opinion below , dismissing Schering’s false advertising claims. Schering sells an...
Nature (Free subscription) | 30/10/2009
In August 2009, asenapine (Saphris; Schering–Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.
Market Watch (Free subscription) | 29/10/2009
SAN FRANCISCO (MarketWatch) -- Priceline.com [s:pcln] will replace Schering-Plough Corp. in the S&P 500 on an undisclosed date, Standard & Poor's said late Thursday. The change stems from Schering-Plough's pending merger with S&P 500 constituent Merck & Co. , the index publisher said. Also, Freeport-McMoRan Copper & Gold Inc. , already a member of the S&P 500, will replace...
Capital Observer (Free subscription) | 29/10/2009
Merck received US anti trust approval of its merger with Schering Plough. They are waiting on Chinese approval, which is a mere formality. The deal will likely close next week. I expect the health care sector to get a boost as it did when the Pfizer/Wyeth deal closed. The boost will likely be smaller as the cash component of this deal is smaller.
BrooklynDodger (Free subscription) | 29/10/2009
BrooklynDodger(s) comment: These novel assay experiments should be related to exposure levels in which toxicity or carcinogenicity is expressed in an intact animal. Toxicology and Applied Pharmacology Volume 241, Issue 2 , 1 December 2009, Pages 230-245 Toxicogenomic analysis of N -nitrosomorpholine induced changes in rat liver: Comparison of genomic and proteomic responses and anchoring to histopathological...
CScout TrendBlog (Free subscription) | 27/10/2009
Bayer Schering Pharma’s World Contraception Day kicks off with online press conference Working in conjunction with Kreative Konzeption and Ketchum, CScout helped organize the online press conference for the annual World Contraception Day which took place on September 24, 2009. The media event featured members of the Youth Task Force (YTF), a group of young regional [...]
DealBook (Free subscription) | 26/10/2009
European antitrust regulators have given their blessing to the $41 billion merger of healthcare giants Merck and Schering-Plough.
Videos